Merck KGaA's Outlook Continues to Be Good: CFO

The video discusses the company's positive outlook, driven by strong growth in the life sciences division, particularly due to COVID-19 related products. It highlights the expected continuation of this trend into 2022, with a focus on vaccinations and boosters. The video also addresses supply chain challenges, especially in semiconductors, and outlines the company's strategy for managing these issues. Finally, it covers the company's portfolio strategy, emphasizing a focus on bolt-on acquisitions rather than major transformational deals.

What percentage of the company's growth is driven by COVID-19 related products?

• 30%

• 70%

• 50%

• 90%

What is the expected contribution from process solutions related COVID sales in 2022?

• 800 million

• 700 million

• 1 billion

• 900 million

How does the company view the role of COVID-19 therapies in their business?

• As having no impact

• As a replacement for vaccinations

• As complementary to vaccinations

• As a major contributor

What is the company's strategy to manage profitability amidst supply chain issues?

• Outsourcing production

• Reducing production

• Increasing prices

• Monitoring inflation and cost hikes

What is the company's focus in the semiconductor business?

• Decreasing demand

• Reducing production

• Investing in additional capacity

• Outsourcing production

What is the company's approach to strengthening its sectors?

• Focusing solely on life sciences

• Bolt-on acquisitions

• Large acquisitions

• Reducing investments

In which areas is the company looking to expand its life science capabilities?

• Multimodality play

• Therapy development

• Vaccine production

• Monoclonal antibodies